551 research outputs found
17-ÎČ-Estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo
In the present study, we have investigated the role of estrogens in the regulation of somatostatin receptor subtype (sst) expression in 7315b PRL- secreting rat pituitary tumor cells in vitro and in vivo. sst were undetectable in freshly dispersed cells of the transplantable 7315b tumor. When 7315b cells were cultured in medium containing 10% FCS, the number of high affinity sst increased with prolonged culture time. However, when the medium was supplemented with 10% horse serum (HS) instead of FCS, no sst were detectable on 7315b cells even after three weeks of culturing. In contrast to HS, FCS contains high E2-levels (HS, 8 pM; FCS, 134 pM). The antiestrogen tamoxifen (0.5 ÎŒM) significantly inhibited the sst number to 50.5% of the value of untreated FCS-grown cells, suggesting that E2 stimulates sst expression in 7315b rat pituitary tumor cells. E2 (l0 nM) induced a rapid increase in sst number in HS-grown 7315b cells. Octreotide (1ÎŒM) significantly inhibited PRL release and the intracellular PRL concentration of 7315b cells that were cultured in medium supplemented with FCS or with HS + l0 nM E2 but not in HS alone. This indicates that the sst present on these cells are biologically active. RT-PCR analysis revealed that none of the five currently known sst subtypes were present in freshly dispersed 7315b pituitary tumor cells. The expression of sst2- and sst3- messenger RNA (mRNA) was unequivocally correlated to the presence of E2 because these sst subtypes were detected only in cells that were cultured for7 and 14 days in medium supplemented with FCS or with HS + 10 nM E2. sst1, sst4 and sst5 messenger RNA could not be detected. The 7315b tumor itself synthesizes and secretes huge amounts of PRL. The high PRL levels in tumor-bearing rats inhibit the ovarian E2-production. No detectable E2 levels could be measured in the serum of 7315b tumor-bearing rats. The sc administration of 20 ÎŒg/day E2-benzoate normalized the circulating E2 levels in 7315b tumor- bearing rats. Moreover, E2-treatment indeed induced sst expression in vivo as shown by ligand binding studies using membrane homogenates and [125I- Tyr3]-octreotide as radioligand and by autoradiography on tissue sections. In agreement with the in vitro studies, the expression of the sst2 subtype was established by RT-PCR analysis in 7315b tumors of E2-treated rats. However, in contrast to the in vitro studies. E2-treatment did not effectuate the expression of the sst3 subtype, suggesting that the in vitro stimulus of E2 is stronger. In conclusion: 1) sst2 and sst3 expression in the 7315b rat prolactinoma model is primarily dependent upon the presence of estrogens; 2) the antihormonal action of octreotide in 7315b tumor cells in vitro is mediated via the sst2 and/or sst3 subtypes; 3) the absence of sst expression in vivo can be explained by the hormonal environment of the 7315b tumor cells. The 7315b tumor cells in vivo may down-regulate their own receptor status via their host, because of the ensuing hyperprolactinemia results in a hypo-estrogenic state.</p
Midgut neuroendocrine tumor patients have a depleted gut microbiome with a discriminative signature
Rationale: When compared to other types of cancer, the prevalence of midgut neuroendocrine tumors (NET) has disproportionally increased over the past decades. To date, there has been very little progress in discovering (epi)genetic drivers and treatment options for these tumors. Recent microbiome research has revealed that enteroendocrine cells communicate with the intestinal microbiome and has provided novel treatment targets for various other cancer types. Hence, our aim was to analyze the role of the gut microbiome in midgut NET patients. Methods: Fecal samples, prospectively collected from patients and control subjects, were analyzed with next generation 16S sequencing. Patients with neuroendocrine carcinomas and recent antibiotics use were excluded. Relevant variables were extracted from questionnaires and electronic health records. Microbial composition was compared between patients and controls as well as between groups within the patient cohort. Results: 87 midgut NET patients and 95 controls were included. Midgut NET patients had a less rich and diverse gut microbiome than controls (p < 0.001). Moreover, we identified 31 differentially abundant species and a gut microbial signature consisting of 17 species that was predictive of midgut NET presence with an area under the receiver operating characteristic curve of 0.863. Gut microbial composition was not directly associated with the presence of the carcinoid syndrome, tumor grade or multifocality. Nonetheless, we did observe a potential link between microbial diversity and the presence of carcinoid syndrome symptoms within the subset of patients with elevated 5-hydroxyindolacetic acid levels. Conclusion: Midgut NET patients have an altered gut microbiome which suggests a role in NET development and could provide novel targets for microbiome-based diagnostics and therapeutics.</p
Interferon-alpha-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas
Interferon-alpha (IFN alpha) may exert direct inhibitory effects on cell
proliferation and on the production of different peptide hormones. We
investigated the effect of IFN alpha on hormone production by 15
GH-secreting pituitary adenomas, 4 clinically nonfunctioning or
gonadotroph pituitary adenomas, and 4 prolactinomas in vitro. In the
GH-secreting pituitary adenoma cultures, a short term (72-h) incubation
with IFN alpha (50-100 U/mL) significantly inhibited GH secretion in 3 of
7 cases and PRL secretion in 6 of 7 cultures. During prolonged incubation
(14 days) with IFN alpha, GH and/or PRL secretion was significantly
inhibited in 7 of 8 cultures (GH, 17-78% inhibition; PRL, 39-88%
inhibition). In the clinically nonfunctioning or gonadotroph cultures
Somatostatin analogues for receptor targeted photodynamic therapy
Photodynamic therapy (PDT) is an established treatment modality, used mainly for anticancer therapy that relies on the interaction of photosensitizer, light and oxygen. For the treatment of pathologies in certain anatomical sites, improved targeting of the photosensitizer is necessary to prevent damage to healthy tissue. We report on a novel dual approach of targeted PDT (vascular and cellular targeting) utilizing the expression of neuropeptide somatostatin receptor (sst2) on tumor and neovascular-endothelial cells. We synthesized two conjugates containing the somatostatin analogue [Tyr3]-octreotate and Chlorin e6 (Ce6): Ce6-K3-[Tyr3]-octreotate (1) and Ce6-[Tyr3]-octreotate-K3-[Tyr3]-octreotate (2). Investigation of the uptake and photodynamic activity of conjugates in-vitro in human erythroleukemic K562 cells showed that conjugation of [Tyr3]-octreotate with Ce6 in conjugate 1 enhances uptake (by a factor 2) in cells over-expressing sst2 compared to wild-type cells. Co-treatment with excess free Octreotide abrogated the phototoxicity of conjugate 1 indicative of a specific sst2-mediated effect. In contrast conjugate 2 showed no receptor-mediated effect due to its high hydrophobicity. When compared with un-conjugated Ce6, the PDT activity of conjugate 1 was lower. However, it showed higher photostability which may compensate for its lower phototoxicity. Intra-vital fluorescence pharmacokinetic studies of conjugate 1 in rat skin-fold observation chambers transplanted with sst2+ AR42J acinar pancreas tumors showed significantly different uptake profiles compared to free Ce6. Co-treatment with free Octreotide significantly reduced conjugate uptake in tumor tissue (by a factor 4) as well as in the chamber neo-vasculature. These results show that conjugate 1 might have potential as an in-vivo sst2 targeting photosensitizer conjugate
Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors
The effects of somatostatin (SS-14 and/or SS-28) and of the three
octapeptide SS-analogs that are available for clinical use (octreotide,
BIM-23014 and RC-160) on hormone release by primary cultures of 15
clinically nonfunctioning pituitary adenomas (NFA), 7 prolactinomas, and 2
insulinomas were investigated. In the pituitary adenoma cultures, a
comparison was made with the effects of the dopamine (DA) agonists
bromocriptine and/or quinagolide. In 5 NFAs, 2 prolactinomas and 1
insulinoma somatostatin receptor (subtype) expression was determined by
ligand binding studies and by in situ hybridization to detect sst1, sst2,
and sst3 messenger RNAs (mRNAs). Four NFA cultures did not secrete
detectable amounts of alpha-subunit, FSH, and/or LH. In the other
cultures, hormone and/or subunit release was inhibited by DA-agonists (10
nM) in 9 of 11, by SS (10 nM) in 7 of 11, and by octapeptide SS-analogs
(10 nM) in 3 of 10 cultures. In three NFA cultures, hormone release was
sensitive to SS but not to SS-analogs. In all cultures, except for one,
DA-agonists were the most effective in inhibiting hormone release. In the
prolactinoma cultures, PRL release was inhibited by DA-agonists (10 nM) in
7 of 7, by SS in 4 of 4, and by octapeptide SS-analogs in 3 of 7 cultures.
A dissociation between the effects of SS and SS-analogs was found in 3
cases. In the cultures sensitive to both bromocriptine and SS-28,
bromocriptine was the most potent compound in 2 out of 4 cultures. In the
2 other cultures, both compounds were equally effective. In 2 insulinoma
cultures, insulin release was inhibited by SS, and by octapeptide
SS-analogs in only one. The presence or absence of an inhibitory effect by
octreotide was in all cases in parallel with the presence or absence of
the inhibitory effect by BIM-23014 and RC-160. Autoradiographic studies
using [125I-Tyr0]SS28 showed specific binding in 4 of 5 NFAs, 1 of 2
prolactinomas, and 1 of 1 insulinoma. Specific [125I-Tyr3]octreotide
binding was found in 2 of 5 NFAs, in 1 of 2 prolactinomas, and in the
insulinoma. Two NFAs showed binding of SS28, but not of the sst2.5
specific ligand octreotide. The tumors showed variable sst1 and/or sst3
mRNA expression, whereas no sst2 expression was found. In conclusion, a
dissociation between the inhibitory effects of SS on the one hand and of
the octapeptide SS-analogs octreotide, BIM-23014 and RC-160 on the other
hand, is observed in a small subgroup of NFAs, prolactinomas, and
insulinomas, suggesting that novel sst subtype specific SS-analogs might
be of benefit in the treatment of selected patients with somatostatin
receptor positive secreting tumors not resp
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors
Background:The mTOR-inhibitor everolimus improves progression-free survival in advanced pancreatic neuroendocrine tumours (PNETs). However, adaptive resistance to mTOR inhibition is described.Methods:QGP-1 and BON-1, two human PNET cell lines, were cultured with increasing concentrations of everolimus up to 22 weeks to reach a dose of 1 ÎŒM everolimus, respectively, 1000-fold and 250-fold initial IC 50. Using total DNA content as a measure of cell number, growth inhibitory dose-response curves of everolimus were determined at the end of resistance induction and over time after everolimus withdrawal. Response to ATP-competitive mTOR inhibitors OSI-027 and AZD2014, and PI3K-mTOR inhibitor NVP-BEZ235 was studied. Gene expression of 10 PI3K-Akt-mTOR pathway-related genes was evaluated using quantitative real-time PCR (RT-qPCR).Results:Long-term everolimus-treated BON-1/R and QGP-1/R showed a significant reduction in everolimus sensitivity. During a drug holiday, gradual return of everolimus sensitivity in BON-1/R and QGP-1/R led to complete reversal of resistance after 10-12 weeks. Treatment with AZD2014, OSI-027 and NVP-BEZ235 had an inhibitory effect on cell proliferation in both sensitive and resistant cell lines. Gene expression in BON-1/R revealed downregulation of MTOR, RICTOR, RAPTOR, AKT and HIF1A, whereas 4EBP1 was upregulated. In QGP-1/R, a downregulation of HIF1A and an upregulation of ERK2 were observed.Conclusions:Long-term everolimus resistance was induced in two human PNET cell lines. Novel PI3K-AKT-mTOR pathway-targeting drugs can overcome everolimus resistance. Differential gene expression profiles suggest different mechanisms of everolimus resistance in BON-1 and QGP-1
Low Circulating IGF-I Bioactivity in Elderly Men is associated with Increased Mortality
Context: Low IGF-I signaling activity prolongs lifespan in certain animal models, but the precise role
of IGF-I in human survival remains controversial. The IGF-I kinase receptor activation assay (IGF-I
KIRA) is a novel method for measuring IGF-I bioactivity in human serum. We speculated that
determination of circulating IGF-I bioactivity is more informative than levels of immunoreactive IGFI.
Objective: To study IGF-I bioactivity in relation to human survival.
Design: Prospective observational study.
Setting: A clinical research center at a university hospital.
Study participants: 376 healthy elderly men (aged 73 to 94 years).
Main outcome Measures: IGF-I bioactivity was determined by the IGF-I KIRA. Total and free IGF-I
were determined by IGF-I immunoassays. Mortality was registered during follow-up (mean 82
months).
Results: During the follow-up period of 8.6 years 170 men (45%) died. Survival of subjects in the
highest quartile of IGF-I bioactivity was significantly better than in the lowest quartile, both in the
total study group (HR = 1.8, (95% CI: 1.2 â 2.8, p = 0.01) as well as in subgroups having a medical
history of cardiovascular disease (HR = 2.4 (95% CI: 1.3 â 4.3, p = 0.003) or a high inflammatory risk
profile (HR = 2.3 (95% CI: 1.2 â 4.5, p = 0.01). Significant relationships were not observed for total
or free IGF-I.
Conclusion: Our study suggests that a relatively high circulating IGF-I bioactivity in elderly men is
associated with extended survival and with reduced cardiovascular risk
Carriers of Loss-of-Function Mutations in ABCA1 Display Pancreatic ÎČ-Cell Dysfunction
OBJECTIVE: Abnormal cellular cholesterol handling in islets may contribute to beta-cell dysfunction in type 2 diabetes. beta-Cell deficiency for the ATP binding cassette transporter A1 (ABCA1), which mediates the efflux of cellular cholesterol, leads to altered intracellular cholesterol homeostasis and impaired insulin secretion in mice. We aimed to assess the impact of ABCA1 dysfunction on glucose homeostasis in humans. RESEARCH DESIGN AND METHODS: In heterozygous carriers of disruptive mutations in ABCA1 and family-based noncarriers of similar age, sex, and BMI, we performed oral glucose tolerance tests (OGTTs) (n = 15 vs. 14) and hyperglycemic clamps (n = 8 vs. 8). RESULTS: HDL cholesterol levels in carriers were less than half those in noncarriers, but LDL cholesterol levels did not differ. Although fasting plasma glucose was similar between groups, glucose curves after an OGTT were mildly higher in carriers than in noncarriers. During hyperglycemic clamps, carriers demonstrated lower first-phase insulin secretion than noncarriers but no difference in insulin sensitivity. The disposition index (a measure of beta-cell function adjusted for insulin sensitivity) of the carriers was significantly reduced in ABCA1 heterozygotes. CONCLUSIONS: Carriers of loss-of-function mutations in ABCA1 show impaired insulin secretion without insulin resistance. Our data provide evidence that ABCA1 is important for normal beta-cell function in human
Standalone vertex ïŹnding in the ATLAS muon spectrometer
A dedicated reconstruction algorithm to find decay vertices in the ATLAS muon spectrometer is presented. The algorithm searches the region just upstream of or inside the muon spectrometer volume for multi-particle vertices that originate from the decay of particles with long decay paths. The performance of the algorithm is evaluated using both a sample of simulated Higgs boson events, in which the Higgs boson decays to long-lived neutral particles that in turn decay to bbar b final states, and pp collision data at âs = 7 TeV collected with the ATLAS detector at the LHC during 2011
Measurements of Higgs boson production and couplings in diboson final states with the ATLAS detector at the LHC
Measurements are presented of production properties and couplings of the recently discovered Higgs boson using the decays into boson pairs, H âÎł Îł, H â Z Zâ â4l and H âW Wâ âlÎœlÎœ. The results are based on the complete pp collision data sample recorded by the ATLAS experiment at the CERN Large Hadron Collider at centre-of-mass energies of âs = 7 TeV and âs = 8 TeV, corresponding to an integrated luminosity of about 25 fbâ1. Evidence for Higgs boson production through vector-boson fusion is reported. Results of combined ïŹts probing Higgs boson couplings to fermions and bosons, as well as anomalous contributions to loop-induced production and decay modes, are presented. All measurements are consistent with expectations for the Standard Model Higgs boson
- âŠ